Institute of Experimental Biomedicine - Chair I, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Sci Rep. 2022 Dec 23;12(1):22266. doi: 10.1038/s41598-022-26821-8.
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however, is understudied. We show that an early platelet increment was not detectable in healthy mice during decitabine treatment. Analyses of bone marrow sections revealed vessels with dilated lumina, decreased cellularity, but increased number of red blood cells and the presence of (pro)platelet-like particles. Taken together, decitabine treatment of healthy mice does not induce an early platelet increment, but affects the bone marrow.
治疗骨髓增生异常综合征包括应用去甲基化药物地西他滨。地西他滨治疗骨髓增生异常综合征患者的早期血小板反应是总生存的预测因子。然而，地西他滨对巨核细胞和骨髓的影响还研究得不够。我们表明，在健康小鼠中，地西他滨治疗期间无法检测到早期血小板增加。骨髓切片分析显示，血管腔扩张，细胞减少，但红细胞数量增加，存在（前）血小板样颗粒。总之，地西他滨治疗健康小鼠不会引起早期血小板增加，但会影响骨髓。
